These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

76 related items for PubMed ID: 23481458

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Attainment of normal lipid levels among patients on lipid-modifying therapy in Hong Kong.
    Ambegaonkar B, Chirovsky D, Tse HF, Lau YK, Tomlinson B, Li SK, Yue CS, Wong TH, Choi MC, Tunggal P, Sazonov V.
    Adv Ther; 2012 May; 29(5):427-41. PubMed ID: 22562782
    [Abstract] [Full Text] [Related]

  • 3. Prevalence of lipid abnormalities and attainment of normal lipid levels among patients with dyslipidaemia: a pooled analysis of observational studies from five Asian countries.
    Unniachan S, Bash LD, Khovidhunkit W, Sri RZ, Vicaldo E, Recto C, Ambegaonkar BM.
    Int J Clin Pract; 2014 Aug; 68(8):1010-9. PubMed ID: 24666791
    [Abstract] [Full Text] [Related]

  • 4. Results of retrospective chart review to determine improvement in lipid goal attainment in patients treated by high-volume prescribers of lipid-modifying drugs.
    Stacy TA, Egger A.
    J Manag Care Pharm; 2006 Aug; 12(9):745-51. PubMed ID: 17249907
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
    Van Ganse E, Laforest L, Burke T, Phatak H, Souchet T.
    Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
    [Abstract] [Full Text] [Related]

  • 7. LDL-C goal attainment among patients newly diagnosed with coronary heart disease or diabetes in a commercial HMO.
    Nag SS, Daniel GW, Bullano MF, Kamal-Bahl S, Sajjan SG, Hu H, Alexander C.
    J Manag Care Pharm; 2007 Oct; 13(8):652-63. PubMed ID: 17970603
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies.
    Roth EM, Rosenson RS, Jones PH, Davidson MH, Kelly MT, Setze CM, Lele A, Thakker K.
    J Clin Lipidol; 2012 Oct; 6(6):534-44. PubMed ID: 23312049
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
    Ferdinand KC, Davidson MH, Kelly MT, Setze CM.
    Am J Cardiovasc Drugs; 2012 Apr 01; 12(2):117-25. PubMed ID: 22263674
    [Abstract] [Full Text] [Related]

  • 13. Prevalence of mixed dyslipidemia among Australian patients undergoing lipid-modifying therapy.
    Colquhoun D, Chirovsky D, Sazonov V, Cui YA, Ambegaonkar B.
    Exp Clin Cardiol; 2013 Apr 01; 18(1):e32-6. PubMed ID: 24294045
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Lipid management in high risk coronary patients: how effective are we at secondary intervention?
    Zhu YY, Hayward PA, Hare DL, Stewart AG, Buxton BF.
    Heart Lung Circ; 2012 Feb 01; 21(2):82-7. PubMed ID: 22153966
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.